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1. Introduction
The global prevalence of cancer is increasing, largely as more 
patients are living into old age. Therefore, gastroenterologists car-
ing for patients with inflammatory bowel disease [IBD] increasingly 
are managing patients with cancer, or a previous history of cancer. 
This often requires joint management with the patient’s oncologist, 
enabling case-by-case decision-making based on the characteristics 
and expected evolution of the index cancer. Previously, no European 
guidelines existed describing the impact of IBD on malignancy. For 
this reason, the European Crohn’s and Colitis Organisation [ECCO] 
Guidelines Committee [GuiCom] decided to elaborate a set of 
Consensus Statements on optimal risk/benefit strategies for treat-
ing IBD patients with cancer or a history of cancer. The develop-
ment of clinical practice guidelines is expensive and time consuming, 
and it is the Committee’s hope that these statements will facilitate 
and accelerate future efforts to elaborate formal guidelines, provid-
ing useful information on areas for which evidence is lacking and 
where controlled studies are needed. The strategy used to produce 
the Consensus Statements involved five steps:
1. Two members of Guicom [VA and RE] identified four main 
topics that needed to be addressed: a] IBD and solid tumours; b] IBD 
and skin and haematological malignancies; c] malignancy related to 
therapy: risk and prevention; and d] management of IBD patients 
with a history of malignancy. During 2014, calls for participation 
in the drafting of consensus statements were issued to ECCO mem-
bers, and selected oncologists known for their expertise and active 
research in the field were invited to join the Consensus. Participants 
were selected by the Committee, and four working groups were cre-
ated, each composed of a chairperson [LE, RE, LB, and VA], two 
ECCO members including young members [Y-ECCO], and one 
or two experienced oncologists. The chairmen and their groups 
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elaborated relevant questions on topics dealing with current practice 
and/or areas of controversy. Participants in the Consensus Process 
were asked to provide answers to the questions based on evidence 
from the literature and their own experience [Delphi procedure].1
2. Working in parallel, the four groups conducted a systematic 
review of the literature on their topic with the appropriate key 
words. The searches targeted Medline/PubMed and the Cochrane 
database, as well as other relevant sources.
3. Provisional statements on the group’s topic were drafted by 
the chairmen. These statements were then reviewed and commented 
on by members of the working group. With the aid of a web-based 
platform [www.cpg-development-org], the review process was later 
extended to applicants not included in the working groups and the 
ECCO national representatives [see Acknowledgments].
4. In January 2015, a meeting [chaired by VA and RE] was held 
in Vienna to revise and approve the statements. Each statement was 
projected on a screen, discussed, and revised until a consensus was 
reached by > 80% of the participants at the meeting. The level of 
evidence supporting each statement was rated in accordance with 
the recommendations of the Oxford Centre for Evidence-based 
Medicine.2 In some areas where the level of evidence is generally 
low, expert opinion was included as appropriate.
5. The final document on each topic was written by the chairper-
son in conjunction with the members of his working group. Consensus 
guideline statements in bold are followed by comments on the evi-
dence and opinion. Statements are intended to be read not in isola-
tion but together with the qualifying comments in the accompanying 
text. The final text was edited by VA and RE to ensure consistency of 
style and terminology and then submitted to the participants for final 
approval. In addition, ECCO has diligently maintained a disclosure 
policy of potential conflicts of interests [CoI]. The conflict of interest 
declaration is based on a form used by the International Committee 
of Medical Journal Editors [ICMJE]. The CoI statement is not only 
stored at the ECCO Office and the editorial office of the Journal of 
Crohn’s and Colitis [JCC] but also open to public scrutiny on the 
ECCO website [https://www.ecco-ibd.eu/about-ecco/ecco-disclosures.
html], providing a comprehensive overview of potential conflicts of 
interest of the consensus participants and guideline authors.
2. IBD and Solid Tumours
2.1. Colorectal cancer
Two recent meta-analyses of cohort studies have clarified the 
increased risk of CRC in patients with IBD. For those with Crohn’s 
disease [CD],3 the excess CRC risk has been estimated at 1.9, 
whereas the risk for small bowel cancer was 27.1. The excess CRC 
risk for patients with UC4 has been estimated at a standardised 
incidence ratio [SIR] of 2.4. Male sex [SIR, 2.6], young age at UC 
diagnosis [SIR, 8.6], and extensive colitis [SIR, 4.8] were the major 
risk factors. Others5 have shown that PSC is a major risk factor for 
CRC in IBD patients, particularly those with UC. The risk of CRC 
is not affected by prior liver transplantation. Time to CRC onset 
was similar in patients with PSC and UC and those with UC alone, 
but the former group was five times more likely to develop CRC. 
A recent meta-analysis of data from population-based studies6 found 
a pooled SIR for CRC of 1.7 [95% confidence interval, 1.2–2.2] in 
all patients with IBD. These reports indicate that the risk of CRC is 
definitely increased in patients with IBD, but not to the extent previ-
ously reported and not in all patients.
Several publications, including the most recent European7 and US8 
guidelines, stress the importance of endoscopy for the surveillance 
and treatment of lesions in patients with IBD. Recommendations for 
cancer surveillance can be found in the 2013 European Evidence-
based Consensus on Endoscopy in IBD.7 Long-term follow-up data 
show that proctocolectomy with removal of the entire colon reduces 
the risk of CRC,9 but other reports, including case series, suggest that 
cancer and/or de novo polyps can still develop in the anal transition 
zone [ATZ]10–12 [EL 3].
A recent study in Japan showed that UC-related CRC patients 
were younger than those with CRC unrelated to UC. They were also 
more likely to have multiple neoplastic lesions and had higher pro-
portions of superficial-type lesions and invasive-type lesions at his-
tology, as well as mucinous or signet-ring cell histotypes. In patients 
with stage 3 CRC, UC-related disease was associated with poorer 
survival than sporadic CRC [43.3% vs 57.4%].13 A  case-control 
study found that, after adjustment for node and metastasis stage, 
the risk of death in CRC patients with IBD was roughly twice as 
high as that of patients whose cancers were sporadic (hazard ratio 
[HR] = 2.011). Stage 3 CRC patients with IBD also had significantly 
decreased survival [23.0 vs 133.9 months, p = 0.008].14
Similar findings emerged in a Danish cohort. CRC patients with 
IBD were younger at cancer diagnosis than their non-IBD counter-
parts. Those with CD had a lower frequency of Duke’s A- and B-stage 
tumours [36% vs 42%] and a higher frequency of Duke’s C- [31% 
vs 27%] and D-stage tumours [23% vs 21%], whereas the frequency 
of unknown-stage tumours [10%] resembled that of non IBD-related 
CRC patients. The 5-year adjusted mortality rate ratios for patients 
with UC or CD were 1.14 (95% confidence interval [CI], 1.03–1.27) 
and 1.26 [95% CI, 1.07–1.49], respectively, compared with patients 
without IBD.15 In contrast, in an Irish population-based study, IBD-
related CRC patients were about 7 years younger at cancer diagnosis 
ECCO Statement 2A
Patients with IBD are at increased risk of developing colorectal 
cancer [CRC] (evidence level [EL] 1) which, in the case of ulcera-
tive colitis [UC], varies with the extent and duration of the disease 
[EL 1], family history of CRC, and the presence/absence of pri-
mary sclerosing cholangitis [PSC] [EL 1]. Over the past 35 years, 
the risk of CRC in patients with IBD has not declined signifi-
cantly, but the risk of dying from CRC has decreased [EL 1]
ECCO Statement 2B
The risk of CRC is highest in UC patients with dysplasia 
detected on colonic biopsies, especially high grade dysplasia 
[EL  3]. Endoscopic surveillance and treatment tailored to the 
individual patient’s risk factor profile are recommended [EL 1]. 
Proctocolectomy abolishes the risk of CRC, but not that of anal 
cancer or cancer of the rectal cuff or ileo-anal pouch in patients 
who have undergone ileal pouch-anal anastomosis
ECCO Statement 2C
On average, patients with IBD who are diagnosed with CRC are 
younger than non IBD-related CRC patients. Overall survival 
following CRC diagnosis in IBD patients is driven primarily by 
age, comorbidities, and cancer stage at diagnosis [EL 3]
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than non-IBD CRC patients, but they survived about 3 years longer. 
Older age, male sex, smoking, and advanced CRC grade and stage 
were independently associated with shorter survival times. When pro-
pensity score matching was used to analyse outcomes, the survival 
times of CRC patients with and without IBD were not significantly 
different.16 Taken together, these results reveal that IBD patients tend 
to develop CRC at younger ages than non-IBD patients. However, no 
effect of IBD on patient survival has been consistently demonstrated.
2.2. Anal, fistula-related, and ileo-anal pouch 
cancers
Anal adenocarcinomas arising from perianal fistulas are a 
rare complication in CD.17,18,19 In a meta-analysis of 20 clini-
cal studies [1965–2008] comprising a total of 40 547 patients 
with CD-associated cancer, the incidence of cancer related to 
CD-associated fistulas was 0.2/1000 patient-years.20 In a 17-year 
follow-up study of 6058 CD patients with perianal and/or enterocu-
taneous fistulas, only 4 developed fistula-associated adenocarcino-
mas. These malignancies developed long after CD diagnosis and 
fistula detection (mean interquartile range [IQR]: 25  years [IQR 
10–38] and 10 years [IQR 6–22], respectively), and the median age 
at cancer diagnosis was 48.3  years [IQR 43–58].21 Fistula-related 
adenocarcinomas can arise in patients with long-standing perianal 
CD, and it may be associated with adenomatous transformation of 
the fistula tract epithelium.22,23 Early disease onset, disease duration 
exceeding 10 years, chronic colitis with high inflammatory activity 
and persistence of chronic fistulas and stenosis seem to be associ-
ated with malignant transformation.24 A systematic review of case 
series and reports published between 1950 and 2008 identified 61 
cases of carcinomas arising in CD-related perineal fistulas, and well 
over half [61%] involved females. At cancer diagnosis, the women 
were significantly younger than their male counterparts [47 vs 
53 years, p < 0.032] and had significantly shorter-duration CD [18 
vs 24 years, p = 0.005]. Most of the tumours were adenocarcinomas 
[59%, n = 36] or squamous-cell carcinomas [31%, n = 19], and the 
involved fistulas usually originated in the rectum [59%, n = 36].25
Fistula-related cancer is associated with non-specific signs and 
symptoms. This complicates and often delays diagnosis, thereby 
worsening the prognosis.26 In a systematic review of 23 reports on 
fistula-related cancer [total n patients: 65], the average duration of 
the involved fistula was 14 years, and the mean delay of cancer diag-
nosis was 11 months.27 In patients with long-standing perianal CD, 
a change in symptoms should always raise the suspicion of cancer.28 
Regular surveillance for ano-rectal carcinoma should be requested 
for all patients with perianal CD. It should include routine biopsy of 
any suspicious lesion29 and a biopsy under anaesthesia or curettage 
of fistula tracts when needed.30,31
2.3. Pouch
Conservative proctocolectomy with IPAA has become the inter-
vention of choice for severe UC requiring surgery.32,33 In a series of 
3203 patients with preoperative diagnoses of IBD who underwent 
restorative proctocolectomy with IPAA between 1984 and 2009, 
the cumulative incidences of pouch neoplasia at 5, 10, 15, 20, and 
25 years were 0.9%, 1.3%, 1.9%, 4.2%, and 5.1%, respectively. Of 
these patients, 38 [1.19%] had pouch neoplasia (adenocarcinoma 
of the pouch and/or ATZ in 11 cases [0.36%], pouch lymphoma in 
1 [0.03%], squamous cell cancer of the ATZ in 3, and dysplasia in 
23 [0.72%]), and this risk for this outcome was observed even in 
patients who had undergone mucosectomy.34 In a systematic review 
of 23 observational studies and case series [total n patients: 2040], the 
pooled prevalence of confirmed dysplasia involving the pouch, ATZ, 
or rectal cuff after restorative proctocolectomy for UC was 1.13% 
[range 0–18.75].35 Branco et al. reported 1 case of rectal cancer in 
the 520 IPAAs performed for UC by their group between 1978 and 
February 2008. Based on their retrospective analysis of this case and 
25 others reported in the literature, they concluded that post-IPAA 
cancer can occur: 1] after mucosectomy or stapled anastomosis; 2] 
after IPAAs performed for UC alone or for UC with neoplasia; and 3] 
regardless of whether the initial cancer or dysplasia involved the rec-
tum.36 Prior colorectal neoplasia is associated with an increased risk 
of ileoanal pouch neoplasia in patients with IBD. A Dutch registry 
study identified 25 cases of pouch neoplasia [including 16 adenocar-
cinomas] in 1200 IBD patients who had had IPAAs [1.83%]. The risk 
was increased approximately 4-fold in those with prior colorectal 
dysplasia and 25-fold in those with a history of CRC.37
There is little evidence to support the need for routine surveillance 
of the pouch and ATZ mucosa in the absence of high-risk features 
[ie type C changes at histology, sclerosing cholangitis, unremitting 
pouchitis].10,38 In patients with high-risk features or who have been 
operated on for dysplasia or cancer, pouch surveillance may be con-
ducted. ECCO endoscopy guidelines suggest that annual surveillance 
in such patients with high risk of pouch neoplasia may be worth-
while, at clinician discretion.7 If dysplasia is noted early after surgery, 
careful annual pouch surveillance is needed,39 with multiple biopsies 
of the ileal reservoir and the anorectal mucosa below the ileo-anal 
anastomosis.40 Finally, the risk of rectal cancer is relatively high in 
IBD patients after subtotal colectomy. In a series of 1439 patients 
with UC, the cumulative probability of developing rectal cancer after 
subtotal colectomy was 17%, 27 years after disease onset.41
2.4. Carcinoid tumours
Carcinoids are rare in IBD,42,43,44,45 and there is no convincing evi-
dence that the two conditions are associated. Thus far no risk factors 
ECCO Statement 2D
In patients with CD, adenocarcinoma complicating perianal 
or enterocutaneous fistula tracts can occur but is rare [EL 1]. 
Persistent chronic fistulas in long-standing CD, especially in 
young women, have been identified as potential risk factors for 
malignant transformation of fistulas [EL 2]
ECCO Statement 2E
Chronic active perianal fistulising disease may be associated 
with advanced cancer stage at the time of diagnosis [EL  3]. 
Regular follow-up is recommended for CD patients with 
chronic persisting perianal fistulas, especially when symptoms 
change [eg new-onset pain] [EL5]. The optimum frequency and 
modalities of surveillance are not known [EL 5]
ECCO Statement 2F
The risk for neoplasia in patients with UC and ileal pouch-anal 
anastomosis [IPAA] is low. A preoperative diagnosis of dyspla-
sia or cancer of the colon or rectum is a risk factor for pouch 
dysplasia or adenocarcinoma [EL 1]
 by guest on February 17, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 
948 V. Annese et al.
for the development of carcinoids in IBD patients have been identi-
fied. The tumours are generally asymptomatic, and almost all are 
discovered incidentally after surgery for IBD. No screening test of 
clear-cut diagnostic value is available.
2.5. Small bowel cancers
About 2% of all gastrointestinal cancers affect the small bowel,46 
and a high percentage of these are adenocarcinomas.47 In a recent 
meta-analysis of 20 clinical studies, the estimated incidence of small-
bowel carcinoma in CD patients—0.3/1000 patient=years [CI, 0.1–
0.5]—was increased by a factor of 18.753 with respect to that found 
in an age-matched standard population.20 More recently in France, a 
nationwide cohort study found incidence rates of small-bowel ade-
nocarcinoma of 0.235 per 1000 patient-years among patients with 
small bowel CD, and 0.464 per 1000 patient-years among those 
whose small-bowel CD had been present for > 8 years. In these two 
populations, the SIRs for small-bowel adenocarcinoma were esti-
mated at 34.9 [95% CI, 11.3–81.5] and 46.0 [95% CI, 12.5–117.8], 
respectively.48 However, although the relative risk is high, the abso-
lute risk of developing small-bowel cancer in CD remains low.20,49
Risk factors reportedly associated with the development of 
small-bowel cancer in CD patients include distal jejunal/ileal CD 
localisation, strictures and chronic penetrating disease, long dis-
ease duration, young age at diagnosis, male sex, use of steroids and 
immunomodulators, small-bowel bypass loops, strictureplasties, 
and environmental factors.50 However, other studies have failed to 
confirm some of these associations. In a 2008 case-control study, 
small-bowel resection and use of aminosalicylates for > 2 years were 
significantly associated with a lower incidence of small-bowel ade-
nocarcinoma (odds ratios [OR] 0.07 and 0.29, respectively). Both 
associations remained significant in multivariate analysis [OR 0.04, 
p = 0.001; OR 0.16, p = 0.02, respectively].51 No significant associa-
tion with duration of CD, age at CD diagnosis, or anatomical area 
of CD involvement emerged from the meta-analysis by Laukoetter 
et al. cited in the previous section.20 In almost all case series reported 
thus far,46,48,50,52,53,54,55,56,57,58,59,60,61,62,63 small-bowel adenocarcinomas 
tended to develop in inflamed intestinal segments. On the whole, 
long-standing CD and stricturing disease seem to be the factors most 
strongly associated with elevated risk of small-bowel cancer.
There is not enough strong evidence to make clear recommen-
dations on primary prevention of small-bowel neoplasia in CD 
patients. Advanced imaging and endoscopic techniques (eg capsule 
endoscopy, double-balloon endoscopy, magnetic resonance imaging 
[MRI], computed tomography [CT]) may allow earlier detection of 
small-bowel neoplasia, but they are too costly and complex to be 
used for routine surveillance of all CD patients with small-bowel 
involvement.
In patients with CD, adenocarcinoma may present on CT or 
MRI as a sacculated loop with asymmetrical thickening57 or as 
a short segment of stenosis mimicking benign fibrostenosis.64,65 
Differentiating a benign inflammatory stricture from an early-stage 
small-bowel tumour can be difficult. Capsule endoscopy can be 
useful for detecting neoplastic lesions, but it does not allow biopsy 
collection. Capsule endoscopy has displayed 83.3% sensitivity 
for tumour detection, with a negative predictive value of 97.6%. 
The specificity and positive predictive value were both 100%.63 
Double-balloon enteroscopy or surgery may be indicated if small-
bowel obstruction occurs during a long-standing remission or if 
non-responsive small-bowel strictures or fistulas are present, since 
either may be associated with small-bowel neoplasia.64,66 The pos-
sibility of small-bowel cancer should be suspected and investigated 
if CD patients develop symptomatic strictures after a prolonged 
symptom-free period or strictures that are unresponsive to medical 
therapy.
2.6. Cholangiocarcinoma
Data from the Swedish Hospital Discharge Register and the Swedish 
Cancer Registry indicate a strong association between UC and extra-
hepatic bile duct cancer [SIR 5.6].67 Analysis of the U.S. Surveillance, 
Epidemiology, and End Results [SEER] Program registry shows that 
intrahepatic cholangiocarcinoma is increased in patients with UC, but 
not those with CD.68 Danish population-based studies have revealed 
that extrahepatic cholangiocarcinoma is increased in patients with UC 
as well as those with CD.69,70 However, in patients who do not have PSC, 
there is no evidence linking cholangiocarcinoma to IBD.71 The effects of 
IBDs on the natural history of PSC and its complications [including 
cholangiocarcinoma] have not been well characterised. Clinical man-
agement of the biliary cancer risk is necessary in all patients with PSC, 
regardless of whether they have IBD.72 Survival after a diagnosis of chol-
angiocarcinoma is poor, even in patients without IBD.
2.7. Gastrointestinal stromal tumours
Gastrointestinal stromal tumours [GIST] are stromal or mesenchy-
mal neoplasms affecting the gastrointestinal tract, typically the sub-
epithelial layers. They represent only 1% of primary gastrointestinal 
cancers.73 A few cases of GIST have been reported in IBD patients: 
they include a solitary GIST of the omentum incidentally found dur-
ing surgical exploration for fulminant UC,74 a GIST of the rectum 
in a patient with UC in remission,75 and a DOG1-expressing GIST 
found in a surgical specimen, 20 cm from the adenocarcinoma, from 
a patient with long-standing UC.76 There is no convincing evidence 
of an association between IBD and GIST.
ECCO Statement 2G
Patients with CD involving the small bowel are at increased 
risk for small bowel neoplasia [EL 1]. Adenocarcinomas are the 
most frequent small-bowel neoplasm in CD patients [EL 3], and 
they usually arise in inflamed segments [EL5]
ECCO Statement 2H
Prolonged duration of stricturing disease may be associated 
with the development of small-bowel cancer in patients with 
CD [EL4]
ECCO Statement 2I
Symptomatic strictures developing after a prolonged remission 
and strictures that are refractory to medical therapy should be 
investigated for underlying small-bowel neoplasia [EL5]
ECCO Statement 2L
Patients with IBD, UC in particular, are at higher risk for chol-
angiocarcinoma than the general population [EL2], and the 
excess risk is caused mainly by the association between these 
cancers and PSC [EL2]
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2.8. Extra-intestinal cancers
A meta-analysis of population-based cohort studies comprising a 
total of 17 052 patients with IBD revealed no increased risk of cancer 
at any site in the IBD population [SIR, 1.10].77 However, when data 
have been analysed by specific cancer type and IBD type, CD patients 
have exhibited increased risk for cancer of the upper gastrointestinal 
tract [SIR 2.87] [particularly the stomach], the lungs [SIR 1.82], and 
the urinary bladder [SIR 2.03], as well as for squamous-cell skin 
cancer [SIR 2.35]. Fistulising forms of CD also seem to be associ-
ated with an increased risk of extra-intestinal cancer.78 The meta-
analysis also found patients with UC to be significantly more likely 
to develop liver–biliary cancer [SIR 2.58] and leukaemia [SIR 2.00], 
although their risk of developing lung cancer is reduced [SIR 0.39, 
95 % CI, 0.20–0.74]. Possible risk factors for these tumours were 
suggested [smoking for the lung and bladder cancers, extra-intestinal 
manifestations of IBD for liver-biliary cancer, and disease location 
for upper GI tract cancer], although no clear evidence is available to 
support these conclusions.77 Tumours of the cervix, ovary, pancreas, 
breast, kidney, and brain have not been found to be associated with 
IBD.77,79
3. IBD AND HAEMATOLOGICAL 
MALIGNANCIES
Patients with IBD are at increased risk for intestinal cancers.50,80 
Recent data suggest that IBD is also associated with excess risk for 
extra-intestinal malignancies, as a result of the state of immune acti-
vation it causes, but conflicting results have been reported on this 
issue.55,77,81
3.1. Epidemiology
According to the 2013 SEER database, the current lifelong 
risk of Hodgkin lymphoma is 0.2%, and the 5-year survival rate 
is 85.3%. Corresponding figures for other haematological malig-
nancies are as follows: non-Hodgkin lymphoma [NHL]: 2.1% and 
69.3%; leukaemia: 1.4% and 57.2%; myeloma: 0.7% and 44.9%.82 
Studies of small patient samples and single-centre series suggest 
that the risk for haematological malignancies is increased in IBD 
patients, but increases have been limited or not been observed in 
most population-based studies.81 Jess et  al., however, analysed a 
population-based cohort of 2325 IBD patients and found that CD 
patients, but not those with UC, were at higher risk for lymphoma 
[SIR 3.01, 95% CI, 1.21–6.19], particularly the non-Hodgkin forms 
[SIR 3.43, 95% CI, 1.38–7.07], and this effect was independent of 
thiopurine exposure. The authors suggested that the apparent lack 
of excess risk reported by other groups might stem from the fact 
that all UC and CD patients were combined and analysed as a single 
group, whereas IBD subgroups might differ in terms of their risks 
for developing specific haematological malignancies. Heterogeneity 
in patient populations and differences in disease presentation may 
also have contributed to the discrepancies.55 Moreover, most of the 
smaller studies are retrospective and often include primary intestinal 
lymphoproliferative disorders, the incidence of which is known to be 
increased in CD patients.83
Differences between IBD patients and the general population, as 
well as between CD and UC patients, also emerged from a meta-
analysis of eight population-based cohort studies comprising nearly 
17 000 patients. A trend toward higher risk for lymphoma [SIR 1.42, 
95% CI, 0.95–2.12] was noted in CD patients, whereas those with 
UC were twice as likely as members of the general population to 
develop leukaemia [SIR 2.00, 95% CI, 1.31–3.06]. However, no sig-
nificant excess risk was observed when UC and CD patients were 
analysed as a single group.77 A  large Finnish study that included 
21 964 IBD patients and 236 129 person-years of follow-up found 
a slightly increased risk of Hodgkin lymphoma among UC patients 
[SIR 2.45, 95% CI, 1.06–4.81]. The likelihood of NHL was slightly 
increased in patients with CD [SIR 2.09, 95% CI, 1.00–3.48], but 
the risk was more pronounced in those over 75 years of age who 
had had CD for more than 3 years [SIR 7.22, 95% CI, 1.97–18.5].84 
A study that included 21 964 IBD patients and 236 129 person-years 
of follow-up found a slightly increased risk of Hodgkin lymphoma 
among UC patients [SIR 2.45, 95% CI, 1.06–4.81]. The likelihood 
of NHL was slightly increased in patients with CD [SIR 2.09, 95% 
CI 1.00–3.48], but the risk was more pronounced in those over 
75 years of age who had had CD for more than 3 years [SIR 7.22, 
95% CI, 1.97–18.5]. Similarly, the risk for lymphoma was increased 
only in CD patients [SIR 3.01, 95% CI, 1.21–6.19] in a Danish 
population-based study.55 On the whole, these observations suggest 
that considering CD and UC as one group may be of limited use 
in estimating excess risk for haematological malignancies, given the 
organ-specific patterns of the two IBDs.
The increased risk of lymphoma in CD patients, as compared 
with the general population and with UC patients, also emerged 
from a Swedish population-based cohort study, which prospectively 
evaluated data recorded for 47 000 patients.85 The SIRs [calculated 
using expected case data derived from the SEER database] for malig-
nant lymphoma were 1.00 [95% CI, 0.8–1.3] and 1.3 [95% CI, 
1.0–1.6] for UC and CD patients, respectively. These figures are con-
sistent with population-based data from Canada, which show excess 
risk for lymphoma in CD patients [particularly males], with an inci-
dence and rate ratio [IRR] of 3.63 [95% , 1.53–8.62%].86 Finally, a 
meta-analysis of 34 studies on the cancer risk associated with CD 
found an increased risk of lymphoma (relative risk [RR] 1.47, 95% 
CI, 1.09–1.98, p = 0.01; 18 790 patients) but not of ‘all haematopoi-
etic’ malignancies [RR 1.13, 95% CI, 0.83–1.53, p  =  0.45; 9112 
patients]. In 9462 immunosuppression-naïve CD patients, the risk of 
lymphoma was twice as high as that of the general population, sug-
gesting that the excess risk is indeed related to CD itself.87
Although lymphoma rates seem to be lower in patients with 
UC, the latter are at increased risk for developing leukaemia. Using 
matched data from four population-based studies, Askling et  al. 
found that leukaemia occurred significantly more often than expected 
ECCO Statement 2M
The overall risk of extra-intestinal cancer in patients with 
IBD is not increased relative to the general population [EL 1]. 
However, analysis by individual cancer sites shows that CD 
patients are more likely to develop cancers of the upper gastro-
intestinal tract, lung, urinary bladder, and non-melanoma skin 
cancers [EL1], and UC is associated with an increased risk of 
liver-biliary tract cancers and leukaemia [EL1]
ECCO Statement 3A
IBD patients show a trend toward higher risks of develop-
ing haematological malignancies. Compared with the general 
population, UC patients are significantly more likely to develop 
leukaemia, whereas those with CD are at higher risk for lym-
phoma, especially non-Hodgkin lymphoma [EL1]
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in UC patients [SIR 1.8].85 Another population-based study analysed 
SEER-Medicare data to determine the risk of myeloid malignancies 
in patients over 67 years of age with autoimmune diseases. This risk 
of acute myeloid leukaemia was increased in patients with UC [OR 
1.72, 95% CI, 1.28–2.31] but not those with CD.88 These data were 
confirmed in another population-based study with an increased risk 
of chronic myelogenous leukaemia [OR 3.5, 95% CI, 1.1–11] and 
acute myeloid leukaemia [OR 3.8, 95% CI, 1.1–13].89
Haematological malignancies-related mortality in IBD patients, 
particularly those with UC, may also be higher than that of the general 
population. In 1986, a standardised mortality ratio [SMR] of 5.3 [95% 
CI, 1.7–12.3] was reported in a cohort of 1248 UC patients with acute 
myeloid leukaemia.90 More recently, a nationwide study conducted on 
2066 UC patients in Italy reported an SMR of 2.8 [95% CI, 1.0–6.1] 
in those with NHL or multiple myeloma.91 A multi-national study con-
ducted by the Porto Paediatric IBD Group found that cancer is the 
second cause of mortality in paediatric IBD patients,92 but the specific 
impact of haematological malignancies was not analysed in detail.
3.2. IBD-specific risk factors
Inflammation and immune activation are involved in lym-
phogenesis. The increased risk of haematological malignancies 
observed in patients with autoimmune diseases93 suggests that these 
disorders may also play a role in IBD-associated tumourogenesis. 
Lymphoproliferative malignancies tend to affect organs where auto-
immune responses occur.81,93 Recent reports of increased rates of 
intestinal lymphatic malignancies at sites of active IBD highlight 
the role of chronic antigen stimulation in the development of HM.83 
Harewood et al. reported pancolitis in over 90% of their UC patients 
with haematological malignancies.94 In addition, the incidence of 
these malignancies among IBD patients in centre/hospital-based 
series [who are more likely to have active/severe disease] is higher 
than that for IBD patients collected from other databases.95
The risk is increased by Epstein-Barr virus [EBV] infection,96,97,98 
and most IBD patients who develop haematological malignancies 
after initiating thiopurine therapy are EBV-positive.81,99 Cases of 
EBV-related lymphoproliferative disorders have also been described 
in immunosuppressed IBD patients.96,97,98
In the largest case-control study conducted thus far on lym-
phoma and IBD [80 lymphoma patients and 159 matched controls], 
age [per decade] [OR 1.83, 95% CI, 1.37–2.43] and male sex [OR 
4.05, 95% CI, 1.82–9.02] were strongly associated with the develop-
ment of lymphoma [p < 0.001]. Current immunosuppressive therapy 
also increased the risk [OR 4.20, 95% CI, 1.35–13.11, p = 0.01]. 
Smoking appeared to exert a protective effect [OR 0.43, 95% CI, 
0.20–0.92, p = 0.03], although this finding probably stemmed from 
a selection bias.97 Male patients with early IBD onset are also at 
increased risk of haematological malignancies.81,88,99,100
Fibrostenotic/complicated CD and the early development of disease 
requiring surgery have been associated with NOD2, which plays an 
important role in bacterial autophagy in the intestine.101 Homozygote 
variants of the NOD2 gene predispose the carrier to CD, but they 
may also facilitate the development of haematological malignancies. 
Homozygotic carriers of the NOD2 variant rs2066847 are reportedly 
at higher risk for developing NHL [OR 3.1, 95% CI, 1.1– 8.8]102 and 
marginal zone lymphoma [OR 8.82, 95% CI, 2.33–33].103 Impaired 
lymphocyte apoptosis caused by unresponsiveness to increased tumour 
necrosis factor [TNF]-alpha signalling is thought to represent a patho-
genetic link between leukaemia and IBD.104 It is also important to note 
that patients with haematological malignancies often suffer from gas-
trointestinal disturbances, including IBD.105
3.3. Clinical Presentation and Diagnosis
Specific criteria for early diagnosis of haematological malignancies 
in IBD patients are lacking.81,83,91,97,106,107 Common signs include anae-
mia, abnormal leucocyte counts, and abnormal morphology of periph-
eral blood leucocytes. Fever, weight loss, and night sweats are typical 
symptoms. Haematological malignancies should be suspected if an 
IBD patient develops unexplained headache, fatigue, acquired adenop-
athy, hepatosplenomegaly, or an unexplained biological inflammatory 
syndrome, with or without increase in blood lactate dehydrogenase 
levels.81,83 These features are also associated with acute inflamma-
tory flares, so differential diagnosis is important to avoid significant 
delays in the diagnosis of the haematological malignancy.81,83,91,97,106,107 
Persistent anaemia without signs or symptoms of active intestinal 
inflammation should also raise the suspicion of haematological malig-
nancy.55,81,91,94,108 A complete workup, assessment of the EBV load, and 
a haematology consultation may be justified.81,83,91,106,107,109
Intestinal and extra-intestinal malignancies may present with 
venous thromboembolism,110 which is known to occur with increased 
frequency in IBD patients. Nevertheless, episodes of deep venous throm-
boembolism that occur without other clear predisposing factors or 
while the intestinal disease is in remission may be a marker of occult 
haematological malignancy and therefore warrant appropriate workup.
3.4. Prevention and risk reduction
There is no gold standard or clear algorithm for identifying IBD patients 
at risk of developing haematological malignancies. Given the increased 
risk observed in IBD patients receiving immunomodulators, combina-
tion of immunosuppressive therapies should be avoided in young men 
who are likely to require prolonged treatment. Early post-mononucleo-
sis lymphoproliferation has been observed in EBV-seronegative patients 
under 35 years of age who were receiving thiopurines,81 suggesting that 
combination treatment should be delayed in these patients or another 
drug [methotrexate] administered. Routine EBV testing may reduce the 
risks of treatment-related lymphoproliferative disease.81
IBD patients who develop lymphoma while on immunosuppres-
sive drugs are often EBV-positive, suggesting a relation between the 
immunosuppression and lymphoma. The link might be due to cyto-
toxic effects on activated T cells and NK cells that diminish the anti-
EBV immune response.111
Controlling active intestinal inflammation may also reduce the 
risk of inflammation-driven haematological malignancies.
3.5. Treatment and prognosis
The treatment and prognosis of haematological malignancies in IBD 
patients are similar to those in individuals without IBD. Haematopoietic 
ECCO Statement 3B
Early disease onset, male gender, and age >65 are risk factors 
for haematological malignancies in IBD patients [EL 3]
ECCO Statement 3C
The possibility of haematological malignancies should be con-
sidered for any IBD patient with persistent haematological 
changes that are unresponsive to treatment, unexplained fever, 
adenopathy, or hepatosplenomegaly. A  complete workup and 
haematological consultation are advised [EL 3]
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stem cell transplantation is an important therapy in patients of all ages. It 
can be performed with both autologous and allogeneic haematopoietic 
stem cells.112 In CD patients with extra-nodal relapsing Hodgkin lym-
phoma, un-manipulated peripheral blood autologous transplants have 
reportedly led to complete treatment-free remission of both diseases.113
4. IBD AND SKIN MALIGNANCIES
4.1. Epidemiology
Current estimates indicate that approximately one in five of the 
general population will develop skin malignancies [melanoma and/or 
NMSC] in the course of their lifetimes; 2% will develop melanomas, and 
91.3% of these individuals will survive for 5 years after the diagnosis.82,114
Most population-based studies have found higher rates of 
NMSC in patients with IBD.77,84,115,116,117 The risk seems to be higher 
in CD patients than in those with UC and it tends to increase with 
age.115,116,118,119 Squamous-cell and basal-cell carcinomas [SCC and 
BCC, respectively] are the most common NMSCs diagnosed in IBD 
patients.77,84,115,116,117 Long et  al.116 analysed data for 108 579 IBD 
patients and 434 233 random matched non-IBD controls using admin-
istrative data from the LifeLink Health Plan Claims Database. After 
adjusting for healthcare utilisation and comorbidities, the IBD group 
displayed a melanoma risk similar to that of the general population 
[adjusted HR 1.15, 95% CI, 0.97–1.36] but had a higher frequency of 
NMSCs [adjusted HR 1.34, 95% CI, 1.28–1.40]. The risk for NMSC 
was increased in both CD [adjusted HR 1.48, 95% CI, 1.39–1.58] 
and UC patients [adjusted HR 1.23, 95% CI, 1.16–1.31].116
Another large population-based study from Canada examined data 
on 9618 IBD patients and 91 378 matched controls. The risk of BCC 
was higher in the IBD group [BCC: HR 1.20, 95% CI, 1.03–1.40] and 
more pronounced in patients with CD [SIR 1.95, 95% CI, 1.50–2.50]. 
The CESAME group reported similar results, with IBD-related increases 
in the risk of NMSC [SIR 2.89, 95% CI, 1.98–4.08] but not of mela-
noma [SIR 0.64, 95% CI, 0.17–1.63] as compared with the general 
population.121 Most studies concur that IBD per se does not increase the 
risk for melanoma,55,77,84,86 but a very large sample size would be needed 
to detect a difference in an outcomes as rare as melanoma.
4.2. IBD-specific risk factors
Chronic inflammatory diseases increase the risk of carcinogen-
esis.50,122 Smoking is a major risk factor for both CD and skin malig-
nancies,123 particularly SCC, and it may also increase the risk of 
NMSC in CD patients, although it has been associated with lower 
risk for acral melanoma.123 Preliminary and experimental studies 
suggest that TNF-alpha signalling has a critical role in the protec-
tion of the skin against oxidative stress.120 Consequently, the specific 
impact of IBD per se on the risk for developing skin malignancies 
is difficult to assess in studies including patients treated with TNF-
alpha inhibitors. It is generally agreed that thiopurines increase the 
risk of NMSC, whereas biologicals increase the risk of melanoma, 
though indirect data debate this as well.77,83,84,115,116,117,121 The latter 
risk is probably related to drug-induced increases in photosensitivity, 
and it increases with the duration of therapy.116 The risk for skin 
cancers associated with thiopurines is related to 6-thioguanine DNA 
photoproducts, which result in selective sensitivity to UVA light.124
Sun exposure plays a pivotal role in most skin cancers.125,126 The 
risk of melanoma is related to repeated burns developing with inter-
mittent sun exposure,125 whereas the risk for NMSC is related to 
cumulative sunlight exposure.126
A genetic predisposition toward skin cell alterations may under-
lie the development of some skin malignancies in IBD patients. 
Owens127 suggested that certain genetic variants may be associated 
with predisposition to both IBD and keratin mutations associated 
with SCC, predisposing to both diseases. The genes encoding kerat-
ins 8 and 18 are located on chromosome 12q, whereas those for all 
other type I keratins are on chromosome 17. An association between 
K8 and IBD has been described.128
4.3. Diagnosis and treatment
The clinical presentation and diagnosis are similar to skin malignan-
cies in patients without IBD, and no specific criteria are available for 
early diagnosis.77,81,83,84,115,116,117
Annual skin screening is important for IBD patients, particularly 
those taking immunosuppressants. The risk for NMSC increases 
with age, especially for IBD patients on thiopurines, so regular der-
matological examination is particularly important in these older 
patients [> 50  years]. Patients should be taught to self-assess any 
visible skin alteration. The screening examination should not be lim-
ited to sun-exposed areas: it must include all areas, including those 
which the patient cannot readily see [ie scalp, back]. Ideally, screen-
ing should be performed by a dermatologist, but it can also be done 
by a general medical practitioner [GMP] or gastroenterologist.81
4.4. Prevention and risk reduction
IBD patients, especially those who are immunosuppressed, should 
avoid prolonged sun exposure and the use of sunbeds and always 
use adequate sunblock protection. IBD patients who have been suc-
cessfully treated for skin malignancies are at risk for recurrence and 
need ongoing follow-up.81 Combined immunosuppression should 
probably be avoided in these patients.
5. MALIGNANCIES RELATED TO IBD THERAPY
Patients with IBD are at risk for malignancy, attributable to chronic 
intestinal or biliary tract inflammation or to the carcinogenic effects 
of immunosuppressant drug therapy.129,130 The latter mechanisms are 
sometimes interlinked, as in certain cases of intestinal primary lym-
phomas.83 Cancers caused by immunosuppressant drugs represent a 
minority of the incident cancers observed in patients with IBD. The 
true risk of cancer related to IBD therapy has been investigated in 
analyses of large medico-administrative databases and data from the 
study of specifically-designed cohorts.
5.1 Overall excess risk of cancer
Thiopurines
Thiopurine cytotoxicity is mediated by the incorporation of 6-thio-
guanine instead of guanine during DNA replication in target cells. 
ECCO Statement 4A
It is unclear whether IBD is an independent risk factor for mela-
noma [EL2], but it increases the risk of non-melanoma skin 
cancers [NMSCs] [EL2]. Squamous-cell carcinoma [SCC] and 
basal-cell carcinoma [BCC] are the most common NMSCs 
occurring in IBD. Advanced age is associated with higher risk 
of NMSC [EL2]
ECCO Statement 5A
Patients with IBD being treated with thiopurines are at increased 
risk for cancer [EL3]. There is currently no evidence that the 
overall risk of cancer is increased in patients being treated with 
anti-TNF agents alone [EL4]
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The error stimulates the mismatch repair system, but repair is incom-
plete and thus leads to cell death instead of recovery.131 Thiopurines 
can promote cancer in a number of ways. Their ability to produce 
carcinogenic mutations of cell DNA is the putative mechanism for 
certain thiopurine-related skin cancers.132 They also impair tumour-
cell immunosurveillance [post-transplant state],133 reduce the num-
ber and/or function of immune cells that prevent cells chronically 
infected by Epstein-Barr virus [EBV] from proliferating,134 and facili-
tate the proliferation of cells with microsatellite instability, which 
evade the cytotoxic effects of thiopurines. The latter phenomenon is 
thought to be responsible for the excess risk of acute myeloid leukae-
mia caused by these drugs.135,136
Six studies conducted in IBD referral centres concluded, however, 
that long-term thiopurine use is not associated with any significant 
increase in the overall risk of cancer.137,138,139,140,141,142 All these stud-
ies were underpowered to detect such an effect, but the issue has 
also been examined in three recent nationwide studies that were 
adequately powered.143,144,145 The first, a nested case-control study 
conducted within the UK’s General Practice Research Database, sug-
gested that the risk of lymphoma, but not that of cancer in general, 
was significantly increased in current azathioprine users, but the 
design of the study did not allow identification of patients exposed 
to these drugs prior to entry into the study observational period.143 
In the other two studies, the risk associated with current thiopurine 
exposure of cancer in general was assessed by multivariate analy-
sis with adjustments for age, sex, and IBD subtype. The excess risk 
in the CESAME cohort was 68%144 and was 41% in the Danish 
study.145 The difference between these figures is presumably related 
to the fact that BCCs were included among the cancers analysed in 
the former study but not in the latter. Past exposure to thiopurines 
was not associated with any excess risk of cancer in either of these 
studies.144,145
Anti-TNF agents
Tumour necrosis factor [TNF]-alpha is a cytokine produced by acti-
vated T cells and macrophages, which exerts necrotising effects on 
tumour cells in vitro. Inhibition of TNF-alpha has therefore been 
hypothesised to increase the overall cancer risk,146 possibly in com-
bination with impaired immunosurveillance of tumour cells. Since 
1995, several studies have investigated the cancer risk associated 
with TNF-alpha antagonists used in IBD. The majority of patients 
treated with these agents in these studies also used [or had used] 
thiopurines, so it is difficult to attribute the findings to anti-TNF 
therapy alone. In addition, most of the studies were not adequately 
powered to demonstrate a mild anti-TNF induced increase in the 
overall risk of cancer. The results of the first meta-analysis that 
looked at this issue were published in 2008. Based on data from con-
trolled trials of infliximab therapy for CD, the incidence of cancer 
[any type] was similar in patients treated with infliximab and those 
who received placebo.148 Comparable findings have emerged from a 
more recent systematic review of pooled data from 22 randomised 
controlled trials, which found no significant difference between anti-
TNF or placebo groups in terms of the frequency of malignancies 
diagnosed within the first year of treatment.149 A pooled analysis of 
data from clinical trials of adalimumab in IBD was also published 
in 2014. It revealed no excess risk of cancer in general related to 
adalimumab monotherapy, but the risk was significantly increased 
in patients receiving adalimumab and immunomodulators.150 Data 
from cohort and case-control studies also suggest that TNF-alpha 
antagonists alone do not significantly increase the overall cancer 
risk in IBD.151,152,153,154,155,156 Finally, a recent adequately powered 
nationwide study in Denmark found no evidence that TNF-alpha 
antagonists increased the overall risk of cancer in IBD patients over 
a median follow-up of 3.7  years.147 Within the confines allowed 
by these limitations, current evidence suggests that TNF inhibition 
alone does not significantly increase the overall long-term [up to 
19 years] cancer risk of IBD patients.147
Methotrexate
No studies have focused specifically on the overall risk of cancer in 
IBD patients exposed to methotrexate monotherapy, largely because 
relatively few patients with IBD are currently treated with this drug 
alone.157 Two studies have looked at the cancer risk in biological 
therapy-naive rheumatoid arthritis [RA] patients who were treated 
with methotrexate at doses similar to those used in IBD,158,159 but 
neither was adequately powered to detect such risk.160
Calcineurin inhibitors [cyclosporin, tacrolimus]
Cyclosporin A  and tacrolimus are used in a minority of patients 
with IBD and usually for short-to-intermediate periods of time. 
Consequently, reliable data on the risks of cancer associated with these 
drugs in IBD are lacking. Calcineurin inhibition is associated with an 
unequivocal excess risk of cancer in the post-transplant state.133,161 The 
de novo malignancies that arise in organ transplant recipients vary 
with treatment duration: melanomas and lymphomas appearing first, 
followed by NMSCs and other solid tumours as therapy continues.162 
The overall excess risk of cancer attributable to the use of calcineurin 
inhibitors has not been well defined for populations being treated for 
specific autoimmune diseases.163,164 This may be due to lower doses and 
shorter treatments episodes, since the malignancy risk associated with 
calcineurin inhibitors is dose and treatment duration dependent.165
5.2. Haematological malignancies
Thiopurines with and without anti-TNF agents
In a recent meta-analysis166 of eight population-based stud-
ies143,145,157,167,168,169 and 10 referral studies,78,109,138,139,141,170,171,172 the 
overall SIR for lymphoma considered in the population studies was 
significantly increased [5.7, 95% CI, 3.2  – 10.1] in IBD patients 
receiving thiopurines, but not in former users or patients who had 
never used these drugs. The absolute risks were globally multiplied 
by a factor of 2 to 3 in men compared with women, irrespective of 
age and drug exposure. Among thiopurine users, the highest abso-
lute risks for lymphoma [any type] were found in patients over 50 
[2.6/1000 patient-years] and in males under the age of 30 [estimated 
crude risk: 1-to-2/1000 patient-years]. The lowest absolute risks were 
observed in middle-aged IBD patients [0.3, 0.6, and 0.9/1000 patient-
years for the 30–39, 40–49 and 50–59 year age classes, respectively]. 
In two studies that considered the potential impact of treatment dura-
tion, the SIR for lymphoma attributable to thiopurine exposure did 
not appear to increase substantially beyond the first year of treatment.
It is not clear whether concomitant anti-TNF treatment increases 
the risk of thiopurine-associated lymphoma, except for the hepato-
splenic T-cell variety, as discussed below. In two nationwide cohort 
ECCO Statement 5B
In IBD patients treated with thiopurines, there is an excess risk 
of lymphoma [EL1], which can be reversed by drug withdrawal 
[EL3]. There is no evidence of an overall excess risk of lymphoma 
in IBD patients treated with anti-TNF agents alone [EL4]
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studies,157,167 the absolute risk of lymphoma in patients receiving TNF 
inhibitors and thiopurines was similar to that of patients treated with 
thiopurines alone. However, in both studies the proportions of patients 
on combined treatment were too low to allow detection of significant 
differences. Indirect evidence is given in the meta-analysis of Siegel 
et al.173 The relative risk of NHL in CD patients being treated with 
TNF antagonists, many of whom were also receiving thiopurines, was 
not significantly greater than the pooled risk for lymphoma observed 
in patients receiving thiopurines alone.173
Thiopurines may also increase the long-term risk of acute myeloid 
leukaemia and severe myelodysplastic syndromes secondary to the pro-
liferation of blood cells whose defective mismatch repair system allows 
them to escape the cytotoxic effect of these drugs.136 In the CESAME 
cohort, the risk for these disorders in former thiopurine users [0.3/1000 
patient-years] was significantly higher than that of never users.135
The 2009 meta-analysis by Siegel et  al. found that combined 
therapy for CD with anti-TNF agents and thiopurines was associ-
ated with an increased risk of NHL, with SIRs of 3.2 vs general 
population [CI, 1.5–6.8] and 1.7 vs CD patients on immunomodula-
tor therapy alone [CI, 0.5–7.1].173 In 2011, however, an analysis of 
data in the Kaiser Permanente database found similarly increased 
incidence rates of lymphoma in IBD patients exposed to thiopurines 
alone and in those on thiopurines plus anti-TNF agents, suggesting 
indirectly that TNF-antagonist monotherapy is not associated with 
any real excess risk of lymphoma.167 The results of some other stud-
ies [population-based,153 single-centre,155 case-control151,152] also sug-
gest that anti-TNF therapy alone is not associated with an increase in 
the risk of lymphoma, leukaemia, or other haematological malignan-
cies.151,152,153,155 However, many of the patients treated with anti-TNF 
agents in these studies were also current or former thiopurine users. 
Finally, in the Danish cohort published in 2014, anti-TNF therapy 
was associated with an adjusted OR for cancers of haematopoietic 
and lymphoid tissues of 0.9 [CI, 0.4–1.9].147
Methotrexate
Thus far, no study has looked specifically at the overall excess risk of 
lymphoma in IBD patients exposed to methotrexate monotherapy. 
Patients with RA have a higher risk of lymphoma than the general 
population, but it is mainly attributed to the severe, chronic inflam-
mation that characterises the disease rather than to its treatment.93 
A 3-year prospective nationwide study conducted in France found 
that the incidence of lymphoma in RA patients treated with metho-
trexate was similar to that expected in the general population.174
Calcineurin inhibitors
No data are available on the risk for haematological malignancies in 
IBD patients exposed to calcineurin inhibitors, but use of these drugs 
during the post-transplant state is known to carry an excess risk 
for NHL.133,175 Compared with post-transplant lymphomas linked to 
thiopurine use, those related to calcineurin inhibitor therapy occur 
earlier, are more likely to involve the lymph nodes and small intestine 
and less likely to occur in the brain, and regress more frequently after 
reduction of immunosuppression.133,176
5.2.1. Thiopurine-related lymphomas
Clinicopathological characterisation of lymphomas diagnosed in 
patients with IBD has distinguished three types of lymphomas that are 
attributable to thiopurine use.157,177 They include: a] post transplant-
like lymphomas,178 which can develop in any patient with chronic 
latent EBV infection and seropositivity—in other words, the majority 
of teenagers and almost all adults over the age of 30; b] post-mononu-
cleosis lymphomas, which occur exclusively in males who convert from 
being EBV-seronegative111,179; and c] hepatosplenic T-cell lymphomas, 
which occur mainly in men under the age of 35 who receive thiopu-
rines, alone or with anti-TNF agents, for more than 2 years.180
5.2.2. Post transplant-like lymphomas
Post transplant-like lymphomas account for almost all thiopurine-
related lymphomas that develop in IBD adults over the age of 30.157 
They are EBV-related and caused primarily by reactivation of a chronic 
latent EBV infection.134 In the early post-transplantation phase, the 
clinical onset of these lymphomas in hematopoietic stem cell recipi-
ents is usually preceded by a progressive rise in the systemic EBV viral 
load.181 The latter parameter thus requires close monitoring in this 
patient population,182 and various strategies for preventing or curing 
this early post-transplant lymphoproliferation have been developed.183 
These approaches have not been evaluated in patients with IBD, 
and their use should not currently be considered in clinical practice. 
Attempts should be made, however, to promptly detect EBV-associated 
lymphoproliferation in IBD patients. The presenting symptoms of these 
malignancies may be non-specific [unexplained fever or fatigue, iso-
lated lymphadenopathy],184 and they are sometimes accompanied by 
mild or overt biological signs of haemophagocytic lymphohistiocyto-
sis.185 When these signs/symptoms develop, measurement of the sys-
temic EBV viral load should be part of the diagnostic workup, which 
should ideally be coordinated jointly with the haematology staff.
5.2.3. Post-mononucleosis lymphomas
These are typically fatal early post-mononucleosis lymphoprolif-
erations that mimic X-linked lymphoproliferations.111 They have been 
reported exclusively in young males who are EBV-seronegative [10% 
to 20% of all males under the age of 30] and have been exposed to 
thiopurines. In this subgroup of the CESAME study population, the 
absolute risk of this rare form of lymphoma was estimated at 3/1000 
patient-years.177 These lymphomas can be prevented by using anti-
TNF agents or other immunosuppressants instead of thiopurines in 
the IBD subgroup known to be at risk.
5.2.4. Hepatosplenic T-cell lymphomas
Hepatosplenic T-cell lymphomas [HSTCLs] occur almost exclu-
sively in males under the age of 35 who are exposed to thiopurines.180 
In this subgroup of the CESAME population, the absolute risk for 
ECCO Statement 5C
Post transplant-like lymphomas caused by the reactivation of 
chronic latent EBV infection cannot be prevented in adult IBD 
patients treated with thiopurines [EL 5]
ECCO Statement 5D
Given the risk of post-mononucleosis lymphoma, alternatives 
to thiopurine therapy should be considered in young male IBD 
patients who are EBV-seronegative [EL5]
ECCO Statement 5E
The risk of hepatosplenic T-cell lymphoma in young males 
being co-treated with thiopurines and anti-TNF agents can be 
reduced by limiting the duration of the combined treatment to 
2 years [EL5]
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HSTCL was approximately 0.1/1000 patient-years in individuals 
treated with thiopurines alone and 0.3/1000 patient-years for those 
treated with thiopurines and anti-TNF agents. In the latter group, 
over 80% of the cases of HSTCL occur after the first 2 years of com-
bination therapy.180 The risk can therefore be reduced by limiting 
the duration of combination therapy in this population to 2 years, 
whenever possible.177
5.3. Skin cancers
5.3.1. Non melanoma skin cancer
NMSCs, which include BCCs and SCCs, are more common than 
all other types of cancer. It is uncertain whether IBD is intrinsically 
associated with an increased risk of NMSC.77,116,186
Thiopurines
Post-transplant patients exposed to thiopurines are at increased 
risk for NMSC, with a predominance of SCCs187 [whereas BCCs 
are more common in the general population]. Data suggesting 
an excess risk of NMSC in IBD patients being treated with thio-
purines have emerged from several studies conducted in the past 
5 years.115,116,117,186 The suspicion has recently been confirmed in a 
meta-analysis, which found a pooled adjusted HR for NMSC in 
thiopurine-treated IBD patients of 2.3. There was a trend towards 
increased ratios in studies from referral centres. In studies detail-
ing NMSC subtypes, BCCs were more frequent than SCCs, but the 
BCC:SCC ratio was nonetheless lower than that observed in the 
general population.188 The carcinogenic effect of thiopurines has 
been attributed to increased UVA-induced DNA damage, increased 
production of reactive oxygen species in skin epithelial cells,124 and 
possibly also direct induction of mutations of the PTCH gene132. 
One nationwide study found a significant excess risk of NMSC in 
IBD patients with past exposure to thiopurines, suggesting that the 
carcinogenic effect of these drugs might persist after withdrawal.186 
However, this issue requires further investigation since no persis-
tent risk was noted in a nested case-control study in the Manitoba 
population117 or in a recent analysis of data from the US Veterans 
Affairs database189.
Anti-TNF agents
A meta-analysis showed that anti-TNF therapy for RA is associ-
ated with an increased risk of NMSC.190 Data from a case-control 
study suggest that the risk for these cancers is also significantly 
increased in IBD patients exposed to these drugs.115 However, this 
result was not confirmed in a study of data from a large medico-
administrative database,116 and a similar picture emerged from a 
recent meta-analysis of controlled trial data on adalimumab.150 The 
latter study revealed a significant excess risk of NMSC in patients 
receiving combination therapy with anti-TNF agents and immu-
nomodulators, but not in those treated with adalimumab alone. In 
light of these conflicting data, it is currently impossible to draw any 
meaningful conclusions on the risk of NMSC related to anti-TNF 
monotherapy.
Methotrexate
There are no specific data on the risk of NMSC related to methotrex-
ate in IBD.
Calcineurin inhibitors
There are no specific data on the risk of NMSC related to calcineu-
rin inhibitor therapy for IBD. However, these drugs are associated 
with an increased risk for NMSC in post-transplant settings133 and 
in autoimmune diseases other than IBD.164,191
5.3.2. Melanoma
The incidence of melanoma is increasing in developed countries. 
The results of a recent meta-analysis indicate that the risk of mela-
noma is mildly increased [37%] in IBD patients, independently of 
the use of biological therapy.192
Thiopurines
In two nationwide studies that assessed the impact of immunosup-
pressant therapy on skin cancer risk,116,193 the incidence of melanoma 
in IBD patients with ongoing exposure to thiopurines was similar to 
that expected in the age- and gender-matched general population, 
before and after adjustment for concurrent anti-TNF treatment.
Anti-TNF agents
In a large nested case-control study performed with data from 
a large health insurance claims database, the use of TNF-alpha 
antagonists was independently associated with an increased mela-
noma risk in patients with IBD [OR 1.9, 95% CI, 1.1–3.3].116 In 
the Danish cohort, the adjusted odds ratio was non-significant [OR 
1.3, 95% CI, 0.6–2.7].147 The most recent systematic reviews in the 
field of rheumatology indicate that the risk of melanoma in patients 
with RA exposed to anti-TNF agents is slightly higher than that of 
patients receiving conventional disease-modifying anti-rheumatic 
drugs [DMARDs].158,190
Methotrexate
No data are available for IBD, but in a small prospective study 
of patients with RA, those treated with methotrexate exhibited a 
significant 3-fold increase in the incidence of melanoma as com-
pared with the general population. However, there was no com-
parator group of patients with RA who were not treated with 
methotrexate.194
Calcineurin inhibitors
There are no specific data on the risk of melanoma related to 
calcineurin inhibitors therapy for IBD but, in solid organ trans-
plant recipients, there is an excess risk attributable to post-
transplant use of immunosuppressants, including calcineurin 
inhibitors.133,195 A recent review of over 35 years of dermatologi-
cal experience found no significant risk of melanoma related to 
cyclosporin A  [at the lower dosages used to treat autoimmune 
disorders].196
ECCO Statement 5F
IBD patients who are receiving thiopurines are at increased risk 
for NMSC [EL3], but it is not clear whether the excess risk 
persists after thiopurine withdrawal [EL3]. It is also unclear 
whether the risk of NMSC is increased by anti-TNF mono-
therapy for IBD [EL3]
ECCO Statement 5G
In patients with IBD, the risk of cutaneous malignant mela-
noma is increased 1.32-fold in those treated with anti-TNF 
agents [EL2], but does not seem to be affected by thiopurine 
exposure [EL3]
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5.3.3. Prevention and detection of skin cancers related to 
immunosuppressant therapy
Risk factors for skin cancers [Bowen’s disease, BCC, SCC, and 
melanoma] include smoking, older age, male sex, fair skin type 
and eyes, red hair, cumulative sun exposure, a childhood history of 
painful or severe sunburns, outdoor occupation and family history 
of skin cancer, Caucasian race, geographical area, atypical moles, 
and several genetic factors [p53 polymorphisms, variations in genes 
encoding enzymes involved in free-radical metabolism].81,187 All 
should be taken into account when immunosuppressant therapy 
is being considered for a patient with IBD. Given the background 
excess risk of skin cancers associated with various immunosuppres-
sants [see above], drugs other than anti-TNF agents and calcineurin 
inhibitors might be safer for use in melanoma survivors and patients 
at high risk for these tumours. Alternatives to thiopurines should 
also be considered in patients with histories of SCC, multiple BCCs, 
or premalignant skin lesions [eg solar keratosis].
In transplant recipients, lifelong sun protection and a yearly 
full-body skin examination are recommended. In patients with 
IBD, sun protections also recommended given the excess risk of 
melanoma related to IBD, and especially if certain medicines are 
utilised [thiopurines, calcineurin inhibitors, anti-TNF agents]. 
Skin surveillance by a dermatologist is reasonable; however, the 
patients to be examined and the frequency of examination must be 
defined. In the meantime, it is reasonable to provide surveillance at 
intervals as defined by a dermatologist on the basis of the patient’s 
specific risk factors for skin cancer [genetic and environmental] 
and the expected impact of the immunosuppressant drugs being 
used.
5.4. Human papiloma virus (HPV)-related dysplasia 
and cancer of the uterine cervix
In female IBD patients, current smoking, age at diagnosis < 20 years, 
extensive disease, and exposure to > 10 prescriptions of oral contra-
ceptives have been identified as risk factors for HPV-related cancer 
and dysplasia of the uterine cervix.197,198
Thiopurines and methotrexate
In organ transplant recipients, the use of thiopurines is associated 
with an increased risk of HPV-related cancer of the uterine cervix.133 
Studies that have addressed the independent role of immunomodu-
lators in the occurrence of HPV-related cervical abnormalities in 
IBD patients have produced conflicting results. A mildly increased 
risk of cervical abnormalities in women with IBD exposed to corti-
costeroids and immunosuppressants was observed in a nested case-
control study in a population-based cohort,198 and similar findings 
[odds ratio: 1.5] emerged from a case-control study conducted in a 
tertiary care centre.199 No significant excess risk was independently 
associated with thiopurine exposure in four other studies [a nested 
case-control study in a tertiary care population,79 a population-
based study that included only a limited number of patients exposed 
to thiopurines,55 and two studies of large medico-administrative 
databases,197,200 one of which also included chronic inflammatory 
diseases other than IBD200]. No data are available regarding the use 
of methotrexate alone in IBD.
Anti-TNF agents
Six studies addressed the impact of immunosuppressant therapy on 
the risk of cervical abnormalities in women with IBD,55,79,197,198,199,201 
but none were able to estimate the specific risk associated with 
anti-TNF therapy because the number of patients treated with TNF 
antagonists, alone or with thiopurines, was too small.
5.4.1. Prevention
HPV infection is considered to be the necessary aetiological agent 
for cervical cancer and intra-epithelial neoplasia. Preventive meas-
ures include HPV vaccination and regular Pap-test screening.202 
These measures will not be discussed here since they are extensively 
reviewed in the 2014 Second European Evidence-based Consensus 
on the prevention, diagnosis, and management of opportunistic 
infections in inflammatory bowel disease, published in 2014.203
5.5. Urinary tract cancers
Transplant recipients exposed to immunosuppressants, including 
thiopurines, are at increased risk for developing urinary tract cancers 
[including those of the bladder and kidney]133,204 and, if the cancer 
is successfully treated, there is a high risk of recurrence during thio-
purine therapy.205 To the best of our knowledge, the relative risk of 
urinary tract cancer in IBD patients associated with thiopurine expo-
sure status has been assessed in only one study from Denmark. The 
adjusted risk was significantly increased [2.4-fold] in current users as 
compared with non-users, whereas the relative risk for former users 
[1.7] was not significantly different from that of non-users.145
6. Management of IBD patients with past 
history of malignancy
The lifetime risk of cancer is rising due to increasing life expec-
tancy and the increased incidence associated with advanced age.206 
For patients who have apparently been cured of cancer, the risk of 
local recurrence or metastatic spread of the original neoplastic dis-
ease must always be considered. In addition, data from registries in 
the SEER Programme suggest that individuals who survive cancer 
are 14% more likely to develop a second malignancy than those in 
the general population, and the development of a first cancer during 
childhood increases the lifelong risk of a second malignancy 6-fold.207
For gastroenterologists caring for patients with IBD, managing 
the disease in patients with a history of cancer or those who develop 
neoplastic disease for the first time can be challenging. Oncologists 
are often uncertain how to deal with IBD in their cancer patients. The 
best course involves joint management by specialists from both fields 
with case-by-case decision making based on the characteristics and 
expected evolution of the index cancer, the probable impact of IBD 
therapy on cancer evolution, and the intrinsic severity of the IBD.
In this context, three major questions require urgent attention 
and will be analysed in the pages that follow. First, what effects 
[if any] do the medical therapies prescribed for IBD have on the 
progression or recurrence of cancer? Second, how should medical 
therapy for IBD be managed for patients with a history of cancer, 
newly diagnosed cancer, or recurrent neoplastic disease? Third, what 
effects [if any] do the treatments used for cancer have on the course 
of concomitant IBD?
ECCO Statement 5H
As soon as IBD is diagnosed, patients should be instructed on 
the lifelong use of sun protection measures [EL5], and regular 
full-body skin examinations should also be considered [EL5]
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6.1. The effects of IBD drug therapy on the risks of 
malignancy progression or recurrence
The development or recurrence of cancer in an IBD patient may 
be unrelated to IBD or its treatment. Alternatively, it may be related 
to the chronic intestinal inflammation that characterises IBD and/
or be influenced by the immunosuppressant drugs used to treat IBD 
[Section 6]. Consensus guidelines have not been issued on the man-
agement of IBD patients with a history of cancer, although several 
expert opinions on this issue have been published recently.129,208,209 
Clinical data on the potentially detrimental effects of immunosup-
pressant therapy come mainly from observational studies of patients 
with rheumatological disease or solid organ transplant recipients. 
The thiopurines are known to have both carcinogenic and anti-
cancer properties210 and, until the 1990s, they were widely admin-
istered to organ transplant recipients. Renal transplant recipients 
with pre-transplant diagnoses of cancer have been shown to be at 
increased risk for cancer occurrence or recurrence compared with 
patients without previous cancer history.205,211 The risk of recurrence 
exceeded 20% for patients who had had melanomas or NMSCs and 
was highest [54%] in the 2 years following completion of chemo-
therapy, decreasing progressively thereafter [to 33% at 2–5  years 
and 13% after 5  years]. As shown in Table 1, the relative risk of 
cancer recurrence in the renal transplant recipients studied by Penn 
et  al.205 varied with the type of cancer. More recently, melanoma 
patients receiving immunosuppressants at the time of diagnosis for 
various reasons have been found to have similar relapse rates but 
significantly higher cancer-related mortality rates [owing to more 
aggressive disease] than controls who had never received these 
drugs [42% vs 23%, respectively, p = 0.01].212 Furthermore, in some 
patients diagnosed with malignancies while using thiopurines, with-
drawal of the latter drugs has reportedly been followed by spontane-
ous resolution of the cancer.213,214
The CESAME study group recently reported the results of a pro-
spective assessment of the risk of new or recurrent cancer in patients 
with IBD and pre-existing cancer who were or were not receiving 
immunosuppressants.215 The original cohort consisted of 17 047 
patients who were enrolled between May 2004 and June 2005 and 
followed up through December 2007; 405 patients had a cancer diag-
nosis before study entry. Incident cancer rates during follow-up were 
21.1/1000 patient-years [PY] and 6.1/1000 PY in patients with or 
without a history of cancer, respectively. The former subgroup had a 
multivariate-adjusted HR for incident cancer of 1.9 [95% CI, 1.2–3.0, 
p = 0.003] as compared with patients without cancer diagnoses. Within 
the group with prior malignancy, the potential impact of immunosup-
pressant therapy on the cancers was investigated by survival analysis 
and a nested case-control study. The 93 [23%] cancer patients who 
received immunosuppressants had appreciably higher rates of new and 
recurrent neoplastic disease [23.1/1000 PY and 3.9/1000 PY, respec-
tively] than the 312 [77%] without prior cancer diagnoses [13.2/1000 
PY and 6.0/1000 PY, respectively]. However, these differences were not 
statistically significant, even when analysis was restricted to patients 
with recently diagnosed cancer [< 2 years before study entry] or when 
those with NMSCs were excluded. The authors concluded that whereas 
prior cancer increases the risk of new/recurrent incident cancer in IBD 
patients, immunosuppressant therapy has no real impact on this risk.
These findings should be considered with caution, however, 
because the subset of patients with previous cancer in this cohort 
was relatively small, and the data obtained are clearly in contrast 
with those emerging from more extensive experience in organ trans-
plant recipients. In addition, 77 [83%] of the 93 patients with prior 
cancers who were receiving immunosuppressants at study entry were 
on thiopurines. It is possible that these drugs were used with greater 
caution in patients with histories of lymphoma or NMSCs [generally 
considered the most common immunosuppressant-promoted can-
cers], and this might have biased the results. The number of patients 
on anti-TNF agents [n = 7] or methotrexate [n = 10] at study entry 
were far too small to allow any conclusions on the risk associated 
with these immunosuppressant drugs.
The risk of new or recurrent cancer during anti-TNF therapy 
has been investigated in a few small, generally underpowered studies 
involving patients with RA. Using data from the British Society for 
Rheumatology Biologics registry, Dixon et al. analysed the risk of 
cancer recurrence in 294 RA patients with prior cancer.216 The inci-
dent malignancy rate was 25.3/1000 PY in the 177 receiving anti-
TNF therapy vs 38.3/1000 PY in the 117 on conventional DMARDs 
[OR for the former approach 0.58, 95% CI, 0.23–1.43]. It is impor-
tant to note, however, that the anti-TNF group had more remote his-
tory of malignancy and a higher rate of incident malignancies among 
patients whose previous tumours were melanomas [3/17, 18% vs 
0/10 in the DMARD group]. In another study, this one based on data 
from the German biologicals registry RABBITT,217 prior malignancy 
was reported by 122 of the 5120 RA patients making up the total 
cohort: at study entry, 58 were receiving anti-TNF therapy and the 
other 55 were on DMARDs. The crude incidence rates of new or 
recurrent malignancies in these two groups were not significantly 
different [45.5/1000 PY vs 31.4/1000 PY, p = 0.6], but the numbers 
in both arms are small. A  similar picture emerged from an obser-
vational study of Swedish RA patients with first primary cancers, 
which revealed no significant differences in cancer stage at diagnosis, 
prognosis, or cancer-related mortality between the 314 who, at the 
Table 1. Risk of cancer recurrence [adapted from Penn I, 1993.205]
Risk Organ/type of cancer
Low [< 10%] Incidental asymptomatic renal tumour
Lymphomas
Testicle
Uterine cervix
Thyroid
Intermediate [11-25%] Uterine body
Colon
Prostate
Breast
High [> 25%] Bladder
Sarcoma
Melanoma and non-melanoma skin cancer
Myeloma
Symptomatic renal carcinoma
ECCO Statement 6A
In IBD patients with a history of cancer, the risk of developing 
new or recurrent cancer is increased 2-fold relative to that of 
IBD patients who have never had cancer, regardless of whether 
or not they receive immunosuppressants [EL 2]
ECCO Statement 6B
Physicians must be aware of the potential impact of immuno-
suppressants on cancers and on the risk of developing a second 
malignancy in cancer survivors [EL 3]
 by guest on February 17, 2016
http://ecco-jcc.oxfordjournals.org/
D
ow
nloaded from
 
Inflammatory Bowel Disease and Malignancies 957
time of cancer diagnosis, were receiving or had received anti-TNF 
therapy and 586 matched biologicals-naïve controls.218
Data on anti-TNF therapy in IBD patients with histories of cancer 
come exclusively from small case series and have thus far been pre-
sented only in abstract form.219,220 The largest of these cohorts is the 
one studied by the Groupe d’Etudes Thérapeutiques des Affections 
Inflammatoires Digestives [GETAID]: it comprised 79 IBD patients 
with recent [< 5 year] history of cancer who were exposed to TNF 
antagonists. Cancer-free survival rates at 1, 2, and 5 years were 96%, 
86%, and 72%, respectively.221 More recently, data from seven aca-
demic medical centres in the USA have been presented with 255 IBD 
patients with previous history of cancer and subsequent exposure 
to anti-TNF, thiopurines or methotrexate [antimetabolite arm] or 
without subsequent immunosuppression exposure [control arm].222 
Patients in the control group were more likely to have later stage 
primary cancers compared with the other study arms [p = 0.0003]. 
Incident cancer rate per 100 person-years for patients exposed to 
anti-TNF was: 2.6 with 795 person-years of follow-up; 14.8 with 
122 person-years of follow-up for patients in the antimetabolite arm; 
and 8.52 with 422 person-years of follow-up for controls. There was 
a significant difference in time to subsequent cancer between groups, 
with patients exposed to anti-TNF being less likely to develop a new 
or recurrent cancer compared with controls [p = 0.0110].
In contrast, a predictive statistical model based on the Adverse 
Event Reporting System of the US Food and Drug Administration 
[currently described only in abstract form] estimated that the risk 
of a second cancer increased 11-fold after 9.5  years of anti-TNF 
therapy.223 Anti-TNF therapy should definitely be avoided in patients 
with a history of melanoma [see section 5.3.2].
6.2. Managing IBD therapy in patients with cancer 
or a history of cancer
There is a dearth of solid data on this issue. Therefore, for 
patients with IBD who develop cancer or have had cancer in the 
past, treatment decisions require close collaboration between gastro-
enterologists and oncologists, and they must be based on a thorough 
knowledge of the individual case, including the activity of the IBD, 
concomitant therapy, patient age, and the type and stage of the can-
cer. The development of a second neoplasm in cancer survivors is one 
of the most serious and lethal complications of cancer therapy. These 
tumours account for about 18% of the incident cancers in the USA 
and are thus more common than first cancers of the breast, lung, and 
prostate.207 Second cancers are not always caused solely by cytotoxic 
treatment of the first tumour: they may also reflect the persistence of 
risk factors [eg lifestyle, host factors, genetic predisposition]. Interest 
is growing in the effects of behavioural and environmental factors. 
More work is needed to define the roles played by certain factors [eg 
diet, physical activity, weight management, sun exposure]. However, 
the influence of excessive alcohol consumption and tobacco use have 
been much more thoroughly explored, and the findings can and 
should be used to influence clinical practice.224
Given the mechanism of action of immunosuppressant agents 
and epidemiological data extrapolated from the organ-transplant 
literature, it is generally agreed that—except in certain cases, which 
will be discussed below--immunosuppressants should be stopped 
until the cancer is controlled. Oncologists prefer to stop thiopurines 
when cancer is diagnosed, in part because of their presumed ability 
to aggravate the bone marrow suppression produced by cytotoxic 
chemotherapy. For patients with incident carcinoma that has been 
successfully treated endoscopically or surgically and carries no risk 
of recurrence [eg sporadic colon polyp], there is no need to withdraw 
immunosuppressant therapy. Greater caution is needed, however, for 
in situ dysplastic lesions of the uterine cervix caused by HPV.81 After 
the cervical lesion has been successfully treated, thiopurines can be 
resumed in these cases with close gynaecological monitoring. Prompt 
discontinuation is indicated if the dysplasia recurs.
NMSCs are very common, and stopping thiopurines does not 
eliminate the risk of their recurrence [as it does with lymphomas].81,225 
Therefore, the risks and benefits of continuing these drugs should be 
weighed carefully in light of the severity of the IBD and the character-
istics of the neoplastic lesions [eg number, disfiguring potential]. More 
specifically, in the presence of more aggressive BCC histotypes [scle-
rosing, metatypic] and/or cancers that are not amenable to surgery 
due to the risk of disfiguration,186,226 possible alternatives to thiopu-
rine therapy [eg methotrexate or anti-TNF agents] should be discussed 
with the patient and used with close dermatological follow-up.
A review of the literature clearly shows that the concomitant 
presence of IBD and cancer often leads oncologists and/or gastro-
enterologists to alter their standard treatment plans. For this reason, 
close cooperation between specialists in the two fields is highly rec-
ommended. An observational study conducted in Denmark found 
that breast cancer patients with CD received radiotherapy less fre-
quently and had higher mortality rates than their non-IBD counter-
parts,227 and retrospective cohort studies in several countries219,220,228 
indicate cancer diagnosis in IBD patients is often followed by marked 
reduction [but rarely complete withdrawal] of immunosuppressant 
therapy and more frequent recourse to surgery and use of steroids.
ECCO Statement 6C
Preliminary data on immune-mediated inflammatory diseases 
and IBD demonstrate no obvious excess risk of developing a 
second [new or recurrent] cancer while being treated with anti-
TNF therapy [EL 4]
ECCO Statement 6D
All cases of cancer in IBD should be managed with multidisci-
plinary support. In general, thiopurines, calcineurin inhibitors, 
and anti-TNF agents should be stopped at least until cancer 
therapy is completed [EL 5]
ECCO Statement 6E
Thiopurines should be withdrawn in IBD patients who develop 
squamous-cell carcinomas, aggressive forms of basal-cell car-
cinomas, and multiple synchronous or sequential lesions. In 
patients with sporadic non-aggressive basal cell carcinoma, thi-
opurines can be continued if no satisfactory therapeutic alterna-
tives are available [EL 5]
ECCO Statement 6F
In patients with active IBD and a history of malignancy, 5-ami-
nosalicylates, nutritional therapies, and local corticosteroids 
can be safely used [EL  3]. In more severe flares that do not 
respond to these treatments, the use of anti-TNF, methotrexate, 
short-term systemic corticosteroids, and/or surgery should be 
considered on a case-by-case basis [EL 5]
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In general, 5-aminosalicylates [5-ASA], nutritional therapies, and 
local corticosteroids [eg budesonide] can be safely used in patients with 
active IBD and a history of malignancy. For more severe flares that 
do not respond to these treatments, anti-TNF agents, methotrexate, 
a short course of systemic corticosteroids, and/or surgery should be 
considered on a case-by-case basis. Regardless of the expected duration 
of the immunosuppressant drug withdrawal period, the choice of an 
immunosuppressant drug that can be initiated or resumed after cancer 
therapy has been completed must be based on the type of cancer.
The decision to resume immunosuppressant therapy in a patient 
who has had cancer should be carefully evaluated, case by case, in a 
multidisciplinary fashion. Particular emphasis should be placed on 
the individual risk of cancer recurrence [Table 1], the potential risk 
posed by each immunosuppressant drug in the setting of the specific 
cancer history [Table 2], and most importantly the amount of time 
that has passed since completion of cancer therapy.
The effects of TNF and anti-TNF agents on malignancy are 
unpredictable.129 TNF can trigger apoptosis through the extrinsic 
pathway by activating caspases 8 and 10,229 and this raises the con-
cern that TNF inhibition might facilitate tumour recurrence, growth, 
and/or metastasis. TNF may also favour neoplastic-cell survival and 
proliferation by activating signalling through the nuclear factor κB 
pathway,230 and inhibition of this effect would thus have positive 
repercussions. Several groups have investigated the potential effects 
on advanced cancer of anti-TNF therapy, alone or combined with 
chemotherapy.231,232,233,234 The use or addition of anti-TNF therapy 
has not been shown to produce any clear benefits thus far, but neither 
has it been shown to accelerate cancer progression or worsen overall 
survival. Infliximab has been successfully used to treat severe colitis 
induced by ipilimumab, a monoclonal antibody used to treat mela-
noma, which is directed against cytotoxic T cell-associated antigen 
4,235,236,237,238,239 and it was not found to adversely affect the clinical 
outcome of the cancer. However, these experiences should be evaluated 
with caution, since all the studies were conducted on relatively small 
patient populations and the findings are based exclusively on short-
term follow-up [given the generally poor prognoses]. Furthermore, 
Lees et  al. have described a case of non small-cell lung carcinoma 
which developed during adalimumab therapy for IBD and regressed 
spontaneously after the anti-TNF therapy was withdrawn.240
The use of systemic corticosteroids in this setting is controversial, 
although these drugs are frequently used by oncologists. In theory, they 
can enhance tumour-cell resistance to apoptosis and decrease immune 
surveillance in general.241 Data from population-based studies suggest 
that prolonged corticosteroid exposure is associated with an excess 
risk for lymphoma, NMSC, and breast cancer.242,243,244 Additional data 
are thus needed for proper evaluation of the safety of corticosteroids 
in the management of active IBD in patients with cancer.
In summary, during the first 2 years after completion of anticancer 
therapy, the first-line therapy for IBD should consist of 5-ASA, local ster-
oid therapy, nutritional therapy, antibiotics, and possibly surgery. If these 
approaches are ineffective, therapy with immunosuppressants can be 
considered. It is important to recall, however, that for patients who have 
had cancer, immunosuppressant therapy is best avoided unless abso-
lutely necessary [Table 2]. Experiences with organ transplant recipients 
[Table 1] indicate that, when the cancer is associated with an intermedi-
ate or high risk of recurrence, it is wiser to wait 5 years before starting 
immunosuppressants. The recommended durations of both waiting peri-
ods are empirical. These data apply mainly to thiopurine therapy, whereas 
evidence for anti-TNF agents and especially vedolizumab is much more 
limited. Resumption of immunosuppressant therapy should be preceded 
by in-depth discussion of risks and alternatives with the oncologist and 
the patient, and it should be initiated with a cautious step-up approach, 
starting with monotherapy [preferably methotrexate when appropriate] 
[Table 2]. Anecdotal data, however, suggest that cautious resumption of 
thiopurines or anti-TNF therapy can be attempted as early as 3 months 
after cessation of chemotherapy.209 Data from small, relatively underpow-
ered series indicate that, in patients with metastatic disease, cancer progres-
sion is not dramatically accelerated by anti-TNF agents. When disabling 
IBD occurs in this setting, improving the patient’s quality of life is probably 
the top priority, which outweighs the above-mentioned contraindications 
to anti-TNF therapy.
6.3. Influence of chemotherapy on IBD
Table 2. Immunosuppressant therapies to use or avoid in IBD patients with a history of cancer [adapted from Beaugerie L 2014215]
Type of cancer Avoid Use with caution Can be used
Lymphoma Thiopurines Anti-TNF, methotrexate, steroids
Acute myeloid leukaemia and severe myelodysplastic 
disorders
Thiopurines Anti-TNF Methotrexate, steroids
Melanoma Anti-TNF Thiopurines, steroids Methotrexate
Non-melanoma skin cancer Thiopurines Anti-TNF, steroids Methotrexate
Urinary tract cancer Thiopurines Anti-TNF Methotrexate, steroids
Other tumours Thiopurines, anti-TNF Methotrexate, steroids
TNF, tumour necrosis factor.
ECCO Statement 6G
Based on data in transplant recipients, physicians should con-
sider delaying the resumption of immunosuppressant therapy 
for IBD in patients being treated for cancer, because of the risk 
of recurrent neoplastic disease, for 2 years following the com-
pletion of cancer treatment [EL 3]. The delay can be extended 
to 5 years if the cancer is associated with an intermediate or 
high risk of recurrence [EL 3]
ECCO Statement 6H
Limited evidence indicates that IBD can be aggravated by hor-
monal therapy, chemotherapy-induced mucositis, or immune 
system-activating therapy, alone or in combination [EL 4]. In 
patients with active disease at cancer diagnosis, remission can 
be induced and maintained thanks to the immunosuppressant 
effects of cancer treatment [despite withdrawal of immunosup-
pressant therapy for IBD] [EL 4]. The impact of targeted anti-
cancer therapy on IBD remains unknown [EL 5]
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Limited data are available on the impact of cancer treatment on 
the course of IBD. Axelrad et al. followed 84 IBD patients who had 
just completed chemotherapy for extra-intestinal solid tumours.222 
Of the 69 patients whose IBD was inactive at baseline, 12 [17.4%] 
experienced flare-ups during 5 years of follow-up. The strongest pre-
dictor of disease flare was the use of hormone therapy, alone or with 
cytotoxic chemotherapy. In contrast, 10 [67%] of the 15 patients 
with active disease at baseline achieved clinical remissions in the 
months following completion of their cancer treatments. Only one of 
these 10 patients had received hormonal monotherapy as opposed to 
all 5 of those who did not achieve remission. In a French case-control 
study,228 the median percentage of years with active disease was not 
different before and after cancer diagnosis [27% vs 19%], and it was 
not significantly different from that of IBD patients without a can-
cer history. However, several groups have reported the development 
or exacerbation of colitis after docetaxel therapy for breast can-
cer,245 ipilimumab for melanoma,235,246,247 sunitinib and sorafinib for 
renal cell carcinoma,248 and rituximab.249,250,251 In contrast, imatinib 
therapy for GISTs has occasionally been reported to exert beneficial 
effects on UC252 and CD.253
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